Manning & Napier Advisors LLC Lowers Holdings in Sanofi (NASDAQ:SNY)

Manning & Napier Advisors LLC cut its holdings in Sanofi (NASDAQ:SNY - Free Report) by 2.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 272,998 shares of the company's stock after selling 7,883 shares during the quarter. Manning & Napier Advisors LLC's holdings in Sanofi were worth $15,140,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in SNY. Price T Rowe Associates Inc. MD lifted its stake in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after acquiring an additional 5,091,304 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Sanofi in the 4th quarter worth approximately $135,933,000. Boston Partners lifted its position in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after purchasing an additional 2,501,073 shares during the period. Magnetar Financial LLC lifted its position in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after purchasing an additional 1,705,148 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in Sanofi by 969.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock worth $45,850,000 after buying an additional 861,770 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on SNY shares. Morgan Stanley set a $56.00 target price on Sanofi in a report on Monday, June 2nd. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. BNP Paribas assumed coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, Guggenheim reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Three analysts have rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $61.50.

Sanofi Stock Performance

Shares of SNY opened at $47.86 on Friday. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The stock has a fifty day moving average price of $51.23 and a 200-day moving average price of $52.03. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The firm has a market cap of $117.37 billion, a PE ratio of 17.09, a P/E/G ratio of 0.98 and a beta of 0.50.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the prior year, the business posted $1.78 EPS. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. Equities research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were given a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.